The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

The APAC countries have diverse populations, ethnicities, and clinical practices. Many of the developed economies in these regions have a growing aging population, given the improvements made in healthcare (Cheng, 2010). Japan is one of the largest markets for cardiovascular devices in the world due to its advanced healthcare system and high pricing. In 2013, Among the emerging markets, which include Brazil, China, and India, China has the largest share in the coronary stents market for treating CAD.

Scope

• An overview of Coronary Stents, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized the APAC Coronary Stents market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Coronary Stents.
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Coronary Stents sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving the APAC Coronary Stents market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in the APAC Coronary Stents market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in the APAC Coronary Stents market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 8
1.1 List of Tables 16
1.2 List of Figures 23

2 Introduction 25
2.1 Catalyst 26
2.2 Related Reports 27

3 Industry Overview 28
3.1 Disease Overview 28
3.2 Clinical Outcomes 29
3.2.1 Treatment Guidelines 29
3.2.2 Treatment Modalities 30
3.3 Procedure Trends 44
3.3.1 Asia-Pacific 46
3.4 Market Access 48
3.4.1 Regulatory Process 49
3.4.2 Physician Decision-Making Process 52
3.4.3 Role of Group Purchasing Organizations 55
3.4.4 Lack of Clinical Data 58
3.4.5 Regional-Level Control 60
3.4.6 Cost Considerations 61
3.4.7 Reimbursement Trends 63
3.5 Regulatory Issues/Recalls 66
3.5.1 Regulatory Issues 66
3.5.2 Product Recalls 67
3.6 Mergers and Acquisitions/ Key Partnerships 67
3.6.1 Medtronic and Covidien 67
3.6.2 Arterial Remodeling Technologies and Terumo Corporation 68
3.6.3 MicroPort Scientific Corporation and Cordis Corporation 68
3.6.4 Alvimedica and CID 69
3.6.5 ITGI Medical and Vascular Solutions 69
3.6.6 Terumo Corporation and Onset Medical Corporation 70
3.6.7 Atrium Medical and Getinge Group 70
3.6.8 C.R. Bard and ClearStream Technologies 70
3.6.9 Biosensors International and Devax, CardioMind, and JW Medical Systems 71
3.6.10 CeloNova Biosciences and Nexeon MedSystems 72
3.6.11 Medtronic and Invatec 72
3.6.12 Micell Technologies and Maxcor Lifescience 73
3.6.13 Boston Scientific Corporation and Guidant Corporation 73
3.6.14 Abbott Vascular and Guidant Corporation 73
3.6.15 Kaneka Corporation and Fujisawa Pharmaceuticals 74
3.7 Economic Impact of Coronary Artery Disease 74
3.7.1 Asia-Pacific 75

4 Unmet Needs 77
4.1 Need for Better Clinical Outcomes in Specific Lesions 77
4.1.1 Chronic Total Occlusions 77
4.1.2 Small-Vessel Coronary Lesions 78
4.1.3 Heavily-Calcified and Uncrossable/Undilatable Lesions 79
4.1.4 Bifurcation Lesions 79
4.1.5 Saphenous Vein Graft Intervention 80
4.2 Eliminating Mechanisms of Failure With Balloon Angioplasty 81
4.3 Late Myocardial Infarction After Stenting 81
4.4 Eliminating the Permanent Polymer 82
4.5 In-Stent Restenosis 83
4.6 Stent-In-Stent Procedures 85
4.7 Prolonged Dual Antiplatelet Therapy 86
4.8 Lack of Homogenous Drug Distribution 87
4.9 Delayed Stent Endothelialization 87
4.10 Negative Vessel Remodeling 88
4.11 Need for Effective Therapy for Specific Patient Populations 88
4.12 Addressing the Complications of Coronary Artery Bypass Grafting 89

5 Market Opportunity Analysis 90
5.1 Improve Stent Design/Platform 90
5.1.1 Stent Coating Technology 91
5.1.2 Bioabsorbable Stent Technology 93
5.1.3 Antiproliferative Drug and Elution Kinetics 94
5.2 Hybrid Stent Systems 96
5.3 Effective Therapies for Challenging Coronary Indications 97
5.3.1 Chronic Total Occlusions 97
5.3.2 Small-Vessel Disease 97
5.3.3 Bifurcation Lesions 98
5.3.4 Diffuse Atherosclerotic Disease 99
5.3.5 Saphenous Vein Graft Intervention 99
5.3.6 Acute Myocardial Infarction 99
5.4 Target Challenging Patient Populations 100
5.5 Emerging Markets 101

6 Market Drivers, Barriers, and Substitutes 102
6.1 Market Drivers 102
6.1.1 Rising Prevalence of Disease 103
6.1.2 Viable Treatment for Challenging Coronary Indications 104
6.1.3 Innovations in Stent Technology 105
6.1.4 Development of Bioabsorbable Stents 107
6.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 109
6.1.6 Potential Cost Savings 110
6.1.7 Use of Imaging Modalities for Accurate Stent Placement 111
6.1.8 Adoption of Stents in the Emerging Markets 111
6.1.9 Launch of Bioabsorbable Stents in US and Japan 112
6.2 Market Barriers 112
6.2.1 Concerns Regarding Overstenting 112
6.2.2 Post-ProceduraI Complications of Drug-Eluting Stenting 113
6.2.3 Risk of Perioperative Adverse Cardiac Events Post-Stenting 113
6.2.4 Slow Adoption of Bioabsorbable Stents 114
6.2.5 Lack of Reimbursement 119
6.2.6 Healthcare Cost-Cutting and Reimbursement 120
6.2.7 Availability of Venture Capital 121
6.2.8 Medical Device Excise Tax 122
6.3 Market Substitutes 122
6.3.1 Drug-Eluting Balloons 122
6.3.2 Liquid Drug Delivery Catheter 123

7 Competitive Assessment 125
7.1 Overview 125
7.2 Trends in Coronary Stent Technology Development 126
7.2.1 Development of Bare Metal Stents 126
7.2.2 Development of Drug-Eluting Stents 128
7.2.3 Development of Bioabsorbable Stents 131
7.2.4 Development of Covered Stents 132
7.2.5 Coronary Stent Technology SWOT Analysis 133
7.3 Regional Company Market Share 134
7.3.1 APAC Market Share 134

8 Pipeline Products 137
8.1 Overview 137
8.2 Pipeline by Stage of Development 137
8.3 Pipeline Product Profiles 140
8.3.1 Bioabsorbable Stents 140
8.3.2 Other Types of Vascular Stents 151

9 Clinical Trial Analysis 157
9.1 Overview 157
9.2 Clinical Trials to Watch 157
9.2.1 Evaluating the Latest and New Generation of Drug-Eluting Stents 157
9.2.2 Bioabsorbable Stent Clinical Trials 159
9.2.3 Evaluating Stenting in Challenging Coronary Indications/Patient Populations 163
9.2.4 Targeting Patient Populations in the APAC Region 165

10 Current and Future Players 167
10.1 Overview 167
10.2 Trends in Corporate Strategy 167
10.3 Company Profiles 170
10.3.1 Abbott Vascular 170
10.3.2 Boston Scientific Corporation 176
10.3.3 Medtronic 183
10.3.4 Alvimedica 189
10.3.5 Amaranth Medical 193
10.3.6 amg International 196
10.3.7 Arterial Remodeling Technologies 200
10.3.8 B. Braun 203
10.3.9 Balton 206
10.3.10 Biosensors International 211
10.3.11 Biotronik 215
10.3.12 Blue Medical 220
10.3.13 Cardionovum 224
10.3.14 C.R. Bard 228
10.3.15 Elixir Medical Corporation 232
10.3.16 eucatech AG 237
10.3.17 Hexacath 241
10.3.18 IRAMED 244
10.3.19 JW Medical Systems 247
10.3.20 Kyoto Medical Planning 250
10.3.21 Lepu Medical Technology 253
10.3.22 MicroPort Scientific Corporation 257
10.3.23 Minvasys 261
10.3.24 MIV Therapeutics 265
10.3.25 Opto Circuits 269
10.3.26 OrbusNeich Medical 273
10.3.27 Relisys Medical Devices 277
10.3.28 REVA Medical 281
10.3.29 Sahajanand Medical Technologies 284
10.3.30 STENTYS 288
10.3.31 Terumo Corporation 292
10.3.32 Translumina 296
10.3.33 Vascular Concepts 300
10.3.34 Other Companies 304

11 Market Outlook 316
11.1 By Market Segment 316
11.1.1 Overview 316
11.1.2 Drug-Eluting Stent Market 317
11.1.3 Bare Metal Stent Market 319
11.1.4 Emerging Stent Technologies 320
11.2 By Indication 322
11.3 By Geography 324
11.3.1 Asia-Pacific 324

12 Appendix 335
12.1 Bibliography 335
12.2 Abbreviations 359
12.3 Report Methodology 366
12.3.1 Overview 366
12.3.2 Coverage 366
12.3.3 Secondary Research 366
12.4 Physicians and Specialists Included in This Study 368
12.4.1 Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI 368
12.4.2 Bernado Cortese, MD, FESC 368
12.4.3 Ricardo A. Costa, MD 368
12.4.4 Thomas Cuisset, MD, PhD, FESC 368
12.4.5 Nobuyuki Komiyama, MD, PhD, FACC, FJCC 368
12.4.6 Roger J. Laham, MD 368
12.4.7 Mark W. Mewissen, MD 368
12.4.8 Gary S. Mintz, MD 368
12.4.9 Tudor C. Poerner, MD 369
12.4.10 David Ramsdale, MD, PhD 369
12.4.11 Gregory A. Sgueglia, MD, PhD 369
12.4.12 Madhukar Shahi, MD 369
12.4.13 Takehiro Yamashita, MD, PhD, FACC 369
12.5 Primary Research 370
12.5.1 Primary Research - Key Opinion Leader Interviews 370
12.5.2 Primary Research Interviews- Physician and Industry Participants 370
12.5.3 Physican Survey 371
12.5.4 Expert Panel Validation 372
12.6 Forecasting Methodology 373
12.7 About the Authors 375
12.7.1 Analysts 375
12.7.2 Global Head of Healthcare 376
12.8 About MediPoint 377
12.9 About GlobalData 377
12.10 Disclaimer 377

List of Tables

Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD* 30
Table 2: Types of CABG 33
Table 3: Complications of CABG 34
Table 4: Drugs Incorporated Into DES 37
Table 5: Types of Lesions Treated Using Atherectomy 41
Table 6: GPOs in the US and EU 56
Table 7: Reimbursement Classification of Medical Devices in Japan 64
Table 8: Direct and Indirect Healthcare Costs of CAD 75
Table 9: Coronary Stent Technology SWOT Analysis, 2014 133
Table 10: Global Coronary Stent Pipeline Products, 2014 139
Table 11: ART18Z SWOT Analysis, 2014 141
Table 12: DREAMS SWOT Analysis, 2014 142
Table 13: Fantom SWOT Analysis, 2014 143
Table 14: Fortitude SWOT Analysis, 2014 144
Table 15: Ideal BioStent SWOT Analysis, 2014 145
Table 16: Igaki-Tamai Stent SWOT Analysis, 2014 147
Table 17: ON-AVS SWOT Analysis, 2014 148
Table 18: Other Companies Developing BAS, 2014 151
Table 19: FOCUS np Eluting Stent SWOT Analysis, 2014 152
Table 20: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014 153
Table 21: Svelte Drug-Eluting Stent SWOT Analysis, 2014 155
Table 22: Clinical Trials Evaluating the Latest and New Generation of DES, 2014 158
Table 23: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014 164
Table 24: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014 166
Table 25: Abbott Vascular Company Profile 170
Table 26: Abbott Vascular Coronary Stent Marketed Products 172
Table 27: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014 175
Table 28: Abbott Vascular SWOT Analysis, 2014 176
Table 29: Boston Scientific Corporation Company Profile 177
Table 30: Boston Scientific Coronary Stent Marketed Products 179
Table 31: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014 182
Table 32: Boston Scientific Corporation SWOT Analysis, 2014 183
Table 33: Medtronic Company Profile 184
Table 34: Medtronic Coronary Stent Marketed Products 186
Table 35: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014 188
Table 36: Medtronic SWOT Analysis, 2014 189
Table 37: Alvimedica Company Profile 190
Table 38: Alvimedica Coronary Stent Marketed Products 191
Table 39: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014 192
Table 40: Alvimedica SWOT Analysis, 2014 193
Table 41: Amaranth Medical Company Profile 194
Table 42: Amaranth Medical Coronary Stent Pipeline Product 194
Table 43: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 195
Table 44: Amaranth Medical SWOT Analysis, 2014 195
Table 45: amg International Company Profile 196
Table 46: amg International Coronary Stent Marketed Products 198
Table 47: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014 199
Table 48: amg International SWOT Analysis, 2014 200
Table 49: Arterial Remodeling Technologies Company Profile 201
Table 50: Arterial Remodeling Technologies Coronary Stent Pipeline Product 201
Table 51: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 202
Table 52: Arterial Remodeling Technologies SWOT Analysis, 2014 202
Table 53: B. Braun Company Profile 203
Table 54: B. Braun Coronary Stent Marketed Products 204
Table 55: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014 205
Table 56: B. Braun SWOT Analysis, 2014 206
Table 57: Balton Company Profile 207
Table 58: Balton Coronary Stent Marketed Products 208
Table 59: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014 210
Table 60: Balton SWOT Analysis, 2014 210
Table 61: Biosensors International Company Profile 211
Table 62: Biosensors International Coronary Stent Marketed Products 213
Table 63: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014 214
Table 64: Biosensors International SWOT Analysis, 2014 215
Table 65: Biotronik Company Profile 216
Table 66: Biotronik Coronary Stent Marketed and Pipeline Products 217
Table 67: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014 219
Table 68: Biotronik SWOT Analysis, 2014 220
Table 69: Blue Medical Company Profile 221
Table 70: Blue Medical Coronary Stent Marketed Products 222
Table 71: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 223
Table 72: Blue Medical SWOT Analysis, 2014 224
Table 73: Cardionovum Company Profile 225
Table 74: Cardionovum Coronary Stent Marketed and Pipeline Products 226
Table 75: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014 227
Table 76: Cardionovum SWOT Analysis, 2014 228
Table 77: C.R. Bard Company Profile 229
Table 78: ClearStream Technologies Coronary Stent Marketed Products 230
Table 79: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014 231
Table 80: C.R. Bard SWOT Analysis, 2014 232
Table 81: Elixir Medical Corporation Company Profile 233
Table 82: Elixir Medical Corporation Coronary Stent Marketed Products 234
Table 83: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 236
Table 84: Elixir Medical Corporation SWOT Analysis, 2014 237
Table 85: eucatech Profile 238
Table 86: eucatech Coronary Stent Marketed Products 239
Table 87: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014 240
Table 88: eucatech SWOT Analysis, 2014 241
Table 89: Hexacath Company Profile 242
Table 90: Hexacath Coronary Stent Marketed Products 243
Table 91: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014 243
Table 92: Hexacath SWOT Analysis, 2014 244
Table 93: IRAMED Company Profile 244
Table 94: IRAMED Coronary Stent Marketed Products 245
Table 95: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014 246
Table 96: IRAMED SWOT Analysis, 2014 247
Table 97: JW Medical Systems Company Profile 248
Table 98: JW Medical Systems Coronary Stent Marketed Product 248
Table 99: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014 249
Table 100: JW Medical Systems SWOT Analysis, 2014 250
Table 101: Kyoto Medical Planning Company Profile 251
Table 102: Kyoto Medical Planning Coronary Stent Pipeline Product 252
Table 103: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014 252
Table 104: Kyoto Medical Planning SWOT Analysis, 2014 253
Table 105: Lepu Medical Technology Company Profile 254
Table 106: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products 255
Table 107: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014 256
Table 108: Lepu Medical Technology SWOT Analysis, 2014 257
Table 109: MicroPort Scientific Corporation Company Profile 258
Table 110: MicroPort Scientific Corporation Coronary Stent Marketed Products 259
Table 111: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 260
Table 112: MicroPort Scientific Corporation SWOT Analysis, 2014 261
Table 113: Minvasys Company Profile 262
Table 114: Minvasys Coronary Stent Marketed and Pipeline Products 263
Table 115: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014 264
Table 116: Minvasys SWOT Analysis, 2014 265
Table 117: MIV Therapeutics Company Profile 266
Table 118: MIV Therapeutics Coronary Stent Marketed Products 267
Table 119: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014 268
Table 120: MIV Therapeutics SWOT Analysis, 2014 269
Table 121: Opto Circuits Company Profile 270
Table 122: Opto Circuits Coronary Stent Marketed Products 271
Table 123: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014 272
Table 124: Opto Circuits SWOT Analysis, 2014 273
Table 125: OrbusNeich Medical Company Profile 274
Table 126: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products 275
Table 127: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 276
Table 128: OrbusNeich Medical SWOT Analysis, 2014 277
Table 129: Relisys Medical Devices Company Profile 278
Table 130: Relisys Medical Devices Coronary Stent Marketed Products 279
Table 131: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014 280
Table 132: Relisys Medical Devices SWOT Analysis, 2014 281
Table 133: REVA Medical Company Profile 282
Table 134: REVA Medical Coronary Stent Pipeline Product 282
Table 135: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014 283
Table 136: REVA Medical SWOT Analysis, 2014 284
Table 137: Sahajanand Medical Technologies Company Profile 285
Table 138: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products 286
Table 139: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014 287
Table 140: Sahajanand Medical Technologies SWOT Analysis, 2014 288
Table 141: STENTYS Company Profile 289
Table 142: STENTYS Coronary Stent Marketed and Pipeline Products 290
Table 143: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014 291
Table 144: STENTYS SWOT Analysis, 2014 292
Table 145: Terumo Corporation Company Profile 293
Table 146: Terumo Corporation Coronary Stent Marketed and Pipeline Products 294
Table 147: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014 295
Table 148: Terumo Corporation SWOT Analysis, 2014 296
Table 149: Translumina Company Profile 297
Table 150: Translumina Coronary Stent Marketed Products 298
Table 151: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014 299
Table 152: Translumina SWOT Analysis, 2014 299
Table 153: Vascular Concepts Company Profile 300
Table 154: Vascular Concepts Coronary Stent Marketed Products 301
Table 155: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014 302
Table 156: Vascular Concepts SWOT Analysis, 2014 303
Table 157: Other Companies in the Coronary Stent Market, North America, 2014 304
Table 158: Other Companies in the Coronary Stent Market, EU, 2014 309
Table 159: Other Companies in the Coronary Stent Market, APAC, 2014 312
Table 160: Other Companies in the Coronary Stent Market, South Africa and South America, 2014 315
Table 161: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 316
Table 162: Global DES Sales ($m) Forecast, 2011-2020 317
Table 163: Global BMS Sales ($m) Forecast, 2011-2020 319
Table 164: APAC Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020 324
Table 165: Coronary Stents Market Sales ($m) Forecast for Japan, 2011-2020 325
Table 166: Coronary Stents Market Sales ($m) Forecast for China, 2011-2020 329
Table 167: Coronary Stents Market Sales ($m) Forecast for India, 2011-2020 332
Table 168: Primary Research Interviews Completed 371
Table 169: Physicians Surveyed, By Country 372

List of Figures

Figure 1: Pathophysiology of CAD 28
Figure 2: CAD Treatment Modalities 31
Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58) 32
Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58) 35
Figure 5: Types of Stents Used to Treat CAD 36
Figure 6: Example of a BMS 37
Figure 7: Example of a DEB 40
Figure 8: Types of Atherectomy 42
Figure 9: Global Coronary Stenting Procedure Volume, 2011-2020 45
Figure 10: APAC Coronary Stenting Procedure Volume, 2011-2020 47
Figure 11: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58) 84
Figure 12: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58) 86
Figure 13: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101) 91
Figure 14: Global Coronary Stents Market Value Share (%), 2013 and 2020 126
Figure 15: APAC Market Share for BMS (%), 2013 135
Figure 16: APAC Market Share for DES (%), 2013 136
Figure 17: Global Coronary Stent Pipeline Products by Stage of Development, 2014 138
Figure 18: Global Coronary Stents Market Revenue ($m), 2011-2020 317
Figure 19: Global DES Market Revenue ($m), 2011-2020 318
Figure 20: Global BMS Market Revenue ($m), 2011-2020 320
Figure 21: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101) 322
Figure 22: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101) 323
Figure 23: APAC Sales ($m) Forecast for Coronary Stents, 2011-2020 325
Figure 24: Japanese Sales ($m) Forecast for Coronary Stents, 2011-2020 327
Figure 25: Chinese Sales ($m) Forecast for Coronary Stents, 2011-2020 330
Figure 26: Indian Sales ($m) Forecast for Coronary Stents, 2011-2020 332